Olinvacimab 产品活性：Olinvacimab (TTAC-0001) 是一种人抗 VEGFR2 单克隆抗体。Olinvacimab 抑制 VEGF 与 KDR 结合，Kd 值为 0.23 nM。Olinvacimab 具有抗血管生成活性。Olinvacimab 可用于复发性胶质母细胞瘤和乳腺癌的研究。 产品来源： https://www.medchemexpress.cn/olinvacimab.html 研究领域：Protein Tyrosine Kinase/RTK 作用靶点：VEGFR In Vitro: Olinvacimab (0-1000 nM) inhibits binding of VEGF to its receptor KDR with a Kd value of 0.23 nM. Olinvacimab inhibits VEGF-165, VEGF-C and VEGF-D binding to VEGFR-2 with IC50 values of 8.7, 6.3 and 7.0 nM, respectively. Olinvacimab (0.5-30 μg/mL; 30 min) inhibits the phosphorylation of VEGFR-2/KDR and ERK. Olinvacimab (1, 15 and 20 mg/mL; 30 min) inhibits VEGF-induced proliferation of HUVEC. Olinvacimab (20 mg/mL; 30 min) inhibits VEGF-stimulated HUVEC migration. Olinvacimab (5, 10 and 20 μg; 20 h) dose-dependently inhibits tube formation and disorders tubular structures. Olinvacimab (1 and 20 μg; 6 d) inhibits hVEGF165-induced rat aortic ring vessel sprouting. In Vivo: Olinvacimab (100 ng; s.c., once) inhibits angiogenesis in vivo. 相关产品：Sorafenib | Lenvatinib | Bevacizumab | Regorafenib | Sunitinib | Nintedanib | Semaxinib | Cabozantinib | Ponatinib | Axitinib | Midostaurin | Chloramphenicol | Pazopanib | Glycine | PD173074 | Tanshinone IIA | Fruquintinib | 5Z-7-Oxozeaenol | Vandetanib | SU 5402 | Linifanib | Foretinib | SPHINX31 | Ripretinib | GW806742X | Dovitinib 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。